The pma for chf is the same as an NDA for a new drug. When a biotech submits an NDA, it is AWAYS immediately followed by a press release. Any one who has ever invested in bio's has seen these New Drug Application announcements. They can be market moving.
Again, Ma doesn't seem to care about transparency IF PMA was submitted; and he implied recently and Larry confirmed on webinar that that was the case.
An approval for CHF would be huge and the PMA, with all its necessary date submitted to the FDA, would be very positive for shareholders.
Why doesn't Ma release this? Why doesn't our lame PR firm insist on PMA news getting to the public?
Wake up Ma
send a note to Ma/Amanda/IR and let them know that if that indeed was submitted it would be considered a material event and they have an obligation to inform the shareholders of such events. they should not be keeping that internal at this juncture